secwatch / observer

8-K filed September 4, 2024, 7:59 PM ET ticker SHPH CIK 0001757499

other material confidence high sentiment positive materiality 0.70

Shuttle Pharma begins Phase 2 glioblastoma trial; regains Nasdaq compliance

Shuttle Pharmaceuticals Holdings, Inc.

Phase 2 trial of Ropidoxuridine for glioblastoma opened at two sites; four more anticipated this month.
40 patients initially randomized to 1,200 mg/day or 960 mg/day; then 14 more on optimal dose.
FDA Orphan Drug Designation granted for Ropidoxuridine; potential marketing exclusivity.
Nasdaq non-compliance resolved after filing re-audited financials and delayed Q2 2023 10-Q.
Trial expected to complete in 18-24 months; primary endpoint survival vs historical controls.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-24-034987
form_type: 8-K
ticker: SHPH
cik: 0001757499
company_name: Shuttle Pharmaceuticals Holdings, Inc.
filed_at: 2024-09-04T23:59:59+00:00
discovered_at: 2026-05-14T18:03:14.426380+00:00
generated_at: 2026-05-31T06:28:22.430823+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-24-034987
json_url: https://secwatch.observer/filing/0001493152-24-034987.json
markdown_url: https://secwatch.observer/filing/0001493152-24-034987.md
text_url: https://secwatch.observer/filing/0001493152-24-034987.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224034987/0001493152-24-034987-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224034987/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GIPR

Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit

GENERATION INCOME PROPERTIES, INC. June 1, 2026, 5:27 PM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

PECE

Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M

Peace Acquisition Corp. June 1, 2026, 5:16 PM ET other_material Items 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MUX

McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M

McEwen Inc. June 1, 2026, 5:14 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-24-034987

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.